Are biomarkers useful for assessing cardiovascular risk in patients with chronic kidney disease?

Current Opinion in Nephrology and Hypertension

Volumn 16, Issue 6, 2007, Pages 506-511

  Rubin, Clifford ^a   Nolin, Thomas D ^a   Himmelfarb, Jonathan ^a  

^a MAINE MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Cardiovascular risk; Chronic kidney disease; End stage renal disease

Indexed keywords

BIOLOGICAL MARKER;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CIGARETTE SMOKING; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART MUSCLE NECROSIS; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; INFLAMMATION; MEDICAL ASSESSMENT; MORTALITY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; PROGNOSIS; RISK FACTORS;

EID: 37349125235     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f0b331     Document Type: Review

References (71)

1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108:2154-2169.
2. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
3. Hallan SI, Coresh J, Astor BC, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17:2275-2284.
4. Culleton BF, Wilson PW. Cardiovascular disease: risk factors, secular trends, and therapeutic guidelines. J Am Soc Nephrol 1998; 9:S5-S15.
5. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116:85-97.
6. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112-S119.
7. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end stage renal disease therapy. Kidney Int 1995; 47:186-192.
8. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285-1295.
9. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatinon cardiovascular events in people with chronic kidney disease. Circulation 2004; 110:1557-1563.
10. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352:2049-2060.
11. Shlipak MG, Wassel Fyr CL, Chertow GM, et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol 2006; 17:254-261.
12. Menon V, Shlipak MG, Wang X, et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007; 147:19-27.
13. Roberts MA, Hare DL, Ratnaike S, Ierino FL. Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis 2006; 48:341-360. This paper reviews cardiovascular biomarkers in patients with CKD. The authors categorize biomarkers into endothelial dysfunction, vascular calcification, endothelial monocyte recruitment, inflammation, oxidative stress, sympathetic overactivity, platelet activation, left ventricular stretch and myocardial necrosis, summarizing the identified cardiovascular predictors of patient outcomes.
14. Sarnak MJ, Coronado BE, Greene T, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002; 57:327-335.
15. Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002; 13:1918-1927.
16. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58:353-362.
17. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11:1735-1743.
18. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63:793-808.
19. Zoccali C. Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 2006; 70:26-33. This paper reviews traditional and emerging risk factors of cardiovascular disease and how they are affected as kidney function declines. It focuses on hyperphosphatemia, hyperparathyroidism, hyperhomocysteinemia, CRP, sympathetic overactivity, endothelial dysfunction and also discusses potential protective strategies being investigated.
20. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006; 113:2335-2362. This is an extensive review of the molecular and practical considerations of cardiovascular biomarkers. The paper summarizes definitions, characteristics of the ideal biomarker and how to measure biomarker performance. This excellent overview includes current biomarkers and future directions including genetic studies, gene expression, proteomics and molecular imaging approaches.
21. Ridker PM, Brown NJ, Vaughan DE, et al. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109:IV6-IV19.
22. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290:898-904.
23. Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003; 290:891-897.
24. Koenig W. Cardiovascular biomarkers: added value with an integrated approach? Circulation 2007; 116:3-5.
25. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 68:89-95.
26. Gutman S, Kessler LG. The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer 2006; 6:565-571.
27. Kalantar-Zadeh K, Ikizler TA, Block G, et al. Malnutrition- inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003; 42:864-881.
28. Jabs WJ, Theissing E, Nitschke M, et al. Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation 2003; 108:1428-1431.
29. Menon V, Greene T, Wang X, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68:766-772.
30. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005; 45:39-47.
31. Enia G, Panuccio V, Mallamaci F, et al. Fibrinogen and calcium x phosphate product are predictors of cardiovascular events in the CAPD population. J Nephrol 2005; 18:764-769.
32. Zoccali C, Mallamaci F, Tripepi G, et al. Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med 2003; 254:132-139.
33. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285:2481-2485.
34. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354:407-413.
35. Kielstein JT, Frolich JC, Haller H, Fliser D. ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? Nephrol Dial Transplant 2001; 16:1742-1745.
36. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358:2127-2128.
37. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421-426.
38. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65:1009-1016.
39. Danielski M, Ikizler TA, McMonagle E, et al. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis 2003; 42:286-294.
40. Himmelfarb J, Ikizler TA, Stenvinkel P, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62:1524-1538.
41. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-167.
42. Schnabel R, Rupprecht HJ, Lackner KJ, et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results fromthe AtheroGene study. Eur Heart J 2005; 26:241-249.
43. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345:1014-1021.
44. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350:655-663.
45. Blankenberg S, McQueen MJ, Smieja M, et al. Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006; 114:201-208.
46. Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005; 46:610-620.
47. Carr SJ, Bavanandan S, Fentum B, Ng L. Prognostic potential of brain natriuretic peptide (BNP) in predialysis chronic kidney disease patients. Clin Sci (Lond) 2005; 109:75-82.
48. Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl JMed 2000; 343:1148-1155.
49. Dogra G, Irish A, Chan D, Watts G. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. Am J Kidney Dis 2007; 49:776-785.
50. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361:827-833.
51. Stenvinkel P, Wang K, Qureshi AR, et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005; 67:2383-2392.
52. Wang AY, Woo J, Lam CW, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005; 20:1676-1685.
53. Zoccali C, Mallamaci F, Tripepi G, et al. Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. J Hypertens 2003; 21:1355-1362.
54. Zoccali C, Mallamaci F, Tripepi G, et al. Prospective study of neuropeptide Y as an adverse cardiovascular risk factor in end-stage renal disease. J Am Soc Nephrol 2003; 14:2611-2617.
55. Sargent D, Allegra C. Issues in clinical trial design for tumor marker studies. Semin Oncol 2002; 29:222-230.
56. Gion M, Boracchi P, Biganzoli E, Daidone MG. A guide for reviewing submitted manuscripts (and indications for the design of translational research studies on biomarkers). Int J Biol Markers 1999; 14:123-133.
57. Anderson NL. The roles of multiple proteomic platforms in a pipeline for new diagnostics. Mol Cell Proteomics 2005; 4:1441-1444.
58. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006; 24:971-983.
59. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355:2631-2639. A total of 3209 patients of the Framingham Heart Study were evaluated using 10 biomarkers (CRP, BNP, Nt-proBNP, aldosterone, renin, fibrinogen, D-dimer, plasminogen-activator inhibitor 1, homocysteine and albumin-to-creatinine ratio), to predict cardiovascular events. The biomarkers that most strongly predicted major cardiovascular events were B-type natriuretic peptide level (adjusted hazard ratio, 1.25) and the urinary albumin-to-creatinine ratio (adjusted hazard ratio, 1.20). The addition of multimarker scores to the conventional risk factors did not add great benefit.
60. Horita S, Nitta K, Kawashima M, et al. C4d deposition in the glomeruli and peritubular capillaries associated with transplant glomerulopathy. Clin Transplant 2003; 17:325-330.
61. Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 2003; 108:250-252.
62. Hanash S. Disease proteomics. Nature 2003; 422:226-232.
63. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature2000; 403:503-511.
64. Liang Y, Diehn M, Watson N, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 2005; 102:5814-5819.
65. Knickerbocker T, Chen JR, Thadhani R, MacBeath G. An integrated approach to prognosis using protein microarrays and nonparametric methods. Mol Syst Biol 2007; 3:123.
66. Ahn AC, Tewari M, Poon CS, Phillips RS. The clinical applications of a systems approach. PLoS Med 2006; 3:e209.
67. White MY, Gundry RL, Cordwell SJ. When does a fingerprint constitute a diagnostic? Lancet 2006; 368:971-973.
68. Gamache PH, Meyer DF, Granger MC, Acworth IN. Metabolomic applications of electrochemistry/mass spectrometry. J Am Soc Mass Spectrom 2004; 15:1717-1726.
69. Colatsky TJ, Sumner S. Metabolic profiling and biomarker discovery. Curr Opin Investig Drugs 2003; 4:262-263.
70. van Ravenzwaay B, Cunha GC, Leibold E, et al. The use of metabolomics for the discovery of new biomarkers of effect. Toxicol Lett 2007; 172:21-28. This paper provides an excellent example of the potential utility of metabolomics in biomarker discovery.
71. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1:845-867.